0.54
-0.0036(-0.66%)
Currency In USD
| Previous Close | 0.54 |
| Open | 0.54 |
| Day High | 0.55 |
| Day Low | 0.53 |
| 52-Week High | 3.89 |
| 52-Week Low | 0.52 |
| Volume | 594,293 |
| Average Volume | 502,509 |
| Market Cap | 22.59M |
| PE | -1.5 |
| EPS | -0.36 |
| Moving Average 50 Days | 0.61 |
| Moving Average 200 Days | 1.16 |
| Change | -0 |
If you invested $1000 in FibroBiologics, Inc. Common Stock (FBLG) since IPO date, it would be worth $30.81 as of September 16, 2025 at a share price of $0.539. Whereas If you bought $1000 worth of FibroBiologics, Inc. Common Stock (FBLG) shares 6 months ago, it would be worth $539.2 as of September 16, 2025 at a share price of $0.539.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
FibroBiologics Leadership Authors Opinion Editorial Highlighting Fibroblast Cells' Therapeutic Advantages Over Traditional Stem Cell Therapies
GlobeNewswire Inc.
Sep 12, 2025 12:30 PM GMT
HOUSTON, Sept. 12, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for
FibroBiologics Announces Positive IND-Enabling Updates Demonstrating Potential of Fibroblast Spheroids in Chronic-Relapse Psoriasis Treatment
GlobeNewswire Inc.
Sep 11, 2025 12:30 PM GMT
Pilot studies underway to advance IND-enabling preclinical developmentHOUSTON, Sept. 11, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 270+ patents issued and pending wi
FibroBiologics Announces Significant Advancements in Bone Marrow Organoid Platform Enabling Development for Cancer and Immune-Related Therapies
GlobeNewswire Inc.
Sep 10, 2025 12:30 PM GMT
Pilot studies have shown encouraging results that are supporting the company’s pre-IND enabling development, marking a critical step toward clinical translation of the Bone Marrow Organoid technologyHOUSTON, Sept. 10, 2025 (GLOBE NEWSWIRE) -- Fibro